Diabetes, colorectal cancer and cyclooxygenase 2 inhibition

International Journal of Clinical Practice

Volumn 62, Issue 5, 2008, Pages 810-815

  Smith, C J ^a   McKay, G A ^b   Fisher, M ^b  

^a HAIRMYRES HOSPITAL   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ACUTE HEART INFARCTION; CANCER INCIDENCE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; DIABETES MELLITUS; DIGESTIVE SYSTEM ULCER; DRUG DOSE COMPARISON; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEALTH PRACTITIONER; HEALTH PROGRAM; HEART INFARCTION; HUMAN; LONG TERM CARE; LOW DRUG DOSE; PATIENT CARE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW; RISK FACTOR; STROKE; TREATMENT OUTCOME;

ANTICARCINOGENIC AGENTS; ASPIRIN; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; CYCLOOXYGENASE 2 INHIBITORS; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; RISK FACTORS;

EID: 42149141282     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01726.x     Document Type: Review

References (36)

1. Kannel WB, McGhee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979 2 : 120 6.
2. Centres for Disease Control and Prevention. Centers for Disease Control and Prevention: Diabetes Surveillance Report. Atlanta, GA : US Department of Health and Human Services, 1999.
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998 339 : 229 34.
4. Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S. Diabetes mellitus and the risk of cancer. Arch Intern Med 2006 166 : 1871 7.
5. Stattin P, Bjor O, Ferrari P et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 2007 30 : 561 7.
6. Rousseau M, Parent M, Pollak MN, Siemiatycki J. Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int J Cancer 2006 118 : 2105 9.
7. Swerdlow AJ, Laing SP, Qiao Z et al. Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br J Cancer 2005 92 : 2070 5.
8. Zendehdel K, Nyren O, Ostenson C, Adami H, Ekbom A, Ye W. Cancer incidence in patients with type 1 diabetes: a population-based cohort study in Sweden. J Natl Cancer Inst 2003 95 : 1797 800.
9. Wideroff L, Gridley G, Mellemkjaer L et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997 89 : 1360 5.
10. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004 159 : 1160 7.
11. Limburg PJ, Vierkant RA, Fredericksen ZS et al. Clinically confirmed type 2 diabetes and colorectal cancer risk: a population-based, retrospective cohort study. Am J Gastroenterol 2006 101 : 1872 9.
12. Harris MI, Eastman RC. Early detection of undiagnosed diabetes mellitus: a US perspective. Diabetes Metab Res Rev 2000 16 : 230 6.
13. Giovannuci E, Pollak MN, Platz EA et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in woman. Cancer Epidemiol Biomarkers Prev 2000 9 : 345 9.
14. Kaaks R, Toniolo P, Akhmedkhanov A et al. Serum C-peptide, insulin-like growth factor (IGF)-1, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000 92 : 1592 600.
15. Probst-Hensch NM, Yuan JM, Stanczyk FZ, Gao Y-T, Ross RK, Yu MC. IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai. Br J Cancer 2001 85 : 1695 9.
16. Palmqvist R, Hallmans G, Rinaldi S et al. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut 2002 50 : 642 6.
17. Ma J, Pollak MN, Giovannuci E et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-1 and IGF-binding protein-3. J Natl Cancer Inst 1999 91 : 620 5.
18. Renehan AG, Shalet SM. Diabetes, insulin therapy, and colorectal cancer. BMJ 2005 330 : 551 2.
19. Watanabe T, Nakaya N, Kurashima K, Kuryama S, Tsubono Y, Tsuji I. Constipation, laxative use and risk of colorectal cancer: the Miyagi Cohort study. Eur J Cancer 2004 40 : 2109 15.
20. Dordanesh M, Camilleri M, Burton DD, Rath-Harvey DM. Pilot study of pathophysiology of constipation among community diabetics. Dig Dis Sci 1998 43 : 2373 9.
21. McTiernan A. Obesity and Cancer: the Risks, Science, and Potential Management Strategies. Oncology 2005 19 : 871 81.
22. Yang Y, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004 127 : 1044 50.
23. Flossman E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007 369 : 1603 13.
24. Peto R, Gray R, Collins R et al. Randomised controlled trial of prophylactic daily aspirin in British male doctors. BMJ 1988 296 : 313 6.
25. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatr 1991 54 : 1044 54.
26. Sheehan KM, Sheahan K, O'Donoghue DP et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999 282 : 1254 7.
27. Yamauchi T, Watanabe M, Kubota T et al. Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer. Dis Colon Rectum 2002 45 : 98 103.
28. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cycoloxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 2004 10 : 8465 71.
29. Arber N, Eagle CJ, Spicak S, Racz I. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006 355 : 885 96.
30. Meric J-B, Rottey S, Olaussen K et al. Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Haematol 2006 59 : 51 64.
31. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005 352 : 1092 102.
32. Solomon SD, McMurray JJV, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005 352 : 1071 80.
33. Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006 113 : 1950 7.
34. Ladabaum U, Scheiman JM, Fendrick AM. Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysis. Am J Med 2003 114 : 546 54.
35. Hur C, Simon LS, Gazelle GS. The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals. Cancer 2004 101 : 189 97.
36. Rostom A, Dube C, Lewin G et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the US Preventative Services Task Force. Ann Intern Med 2007 146 : 376 89.